A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305, USA.
Biological psychiatry (Impact Factor: 10.26). 02/2012; 71(11):956-61. DOI: 10.1016/j.biopsych.2012.01.014
Source: PubMed


An imbalance in the excitatory/inhibitory systems with abnormalities in the glutamatergic pathways has been implicated in the pathophysiology of autism. Furthermore, chronic redox imbalance was also recently linked to this disorder. The goal of this pilot study was to assess the feasibility of using oral N-acetylcysteine (NAC), a glutamatergic modulator and an antioxidant, in the treatment of behavioral disturbance in children with autism.
This was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autistic disorder. Subjects randomized to NAC were initiated at 900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks and 900 mg three times daily for 4 weeks. The primary behavioral measure (Aberrant Behavior Checklist [ABC] irritability subscale) and safety measures were performed at baseline and 4, 8, and 12 weeks. Secondary measures included the ABC stereotypy subscale, Repetitive Behavior Scale-Revised, and Social Responsiveness Scale.
Thirty-three subjects (31 male subjects, 2 female subjects; aged 3.2-10.7 years) were randomized in the study. Follow-up data was available on 14 subjects in the NAC group and 15 in the placebo group. Oral NAC was well tolerated with limited side effects. Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96).
Data from this pilot investigation support the potential usefulness of NAC for treating irritability in children with autistic disorder. Large randomized controlled investigations are warranted.

Download full-text


Available from: Lawrence Fung,
1 Follower
83 Reads
    • "Dimensional evaluation can be a more successful approach to encompass the features of RRBs than using diagnostic categories in research and clinical settings. In fact, various studies have used the RBS-R as a simple, useful instrument for evaluating RRBs in clinical trials on ASD treatment efficacy (Anagnostou et al., 2012; Dawson et al., 2010; Hardan et al., 2012), examinations of RRB subcategories (Bishop et al., 2012; Lam & Aman, 2007; Lam, Bodfish, & Piven, 2008), and research on the relationship between RRBs and associated ASD clinical features (Gabriels, Cuccaro, Hill, & Ivers, 2005). The RBS-R-Japanese version (RBS-R-J) has already been translated, back-translated, and authorized. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Restricted and repetitive behaviors (RRBs) constitute a core symptom of autism spectrum disorder (ASD). The Repetitive Behavior Scale-Revised (RBS-R) is a widely used questionnaire administered by parents or caregivers to assess RRBs in individuals with ASD. This study evaluated the psychometric properties of the RBS-R Japanese Version (RBS-R-J). The ASD and non-ASD groups comprised 274 and 36 participants, respectively. We examined corrected item-total correlation, Cronbach's alpha, and RBS-R-J scores of different diagnostic groups, as well as correlations between RBS-R-J scores and intelligence quotient (IQ), autistic symptoms, adaptive/maladaptive functioning, aberrant behaviors, and sensory processing. All items showed moderate corrected item-total correlations. Cronbach's alpha coefficient was .93. We found significant differences in the mean RBS-R-J scores of the low-functioning ASD group and the intellectual disabilities group, and of low-functioning and high-functioning ASD groups. RBS-R-J scores negatively correlated with IQ and scores on the Sensory Profile (Japanese version) and Adaptive Behavior Composite of the Maladaptive Behavior Index of the Vineland Adaptive Behavior Scales-Second Edition (VABS-II; Japanese version), but positively correlated with scores on the peak and current symptoms subscales of the Pervasive Developmental Disorders Autism Society Japan Rating Scale, the VABS-II, and the Aberrant Behavior Checklist-Community (Japanese version). From these results, we conclude that RBS-R-J showed good reliability, diagnostic validity, and convergent validity, indicating that it is a reliable, valid instrument for use among ASD individuals in clinical and research settings.
    Research in Autism Spectrum Disorders 07/2015; 15. DOI:10.1016/j.rasd.2015.01.002 · 2.96 Impact Factor
  • Source
    • "The presence of such a correlation would be evidence in favor of the correctness of our assumptions. Second, the literature has some indications of poss itive results of antioxidant therapy in early childhood autism (Chez et al., 2002; Dolske et al., 1993; Morris and Agin, 2009; Yui et al., 2012; Hardan et al., 2012). It is of interest to study the impact of antioxidant therr apy in a sample of children who have undergone assessment of the genomic dose of active ribosomal genes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ribosomal genes (RG), or rRNA genes, in eukaryotic genomes are represented by numerous tandem repeats, of which only a portion are transcriptionally active. The number of active copies is a constant feature of genome genome determining the cell’s ability for the rapid synthesis of proteins needed to overcome the effects of stress. A low number of active RG copies leads to reduced stress resistance and elevated risk of multifactorial diseases (MFDs). Oxidative stress (OS) in the brain cells is believed to be involved in the pathogenesis of infantile autism (IA) and schizophrenia, that is, MFDs with severe genetic predisposition. With autism, OS markers are detected almost in every study, while with schizophrenia the OS data are contradictory. In a sample of patients with schizophrenia, we previously found a significantly higher quantity of active RG copies than in the population on average. In this work, we have determined the number of active RG copies in a sample of patients with IA (n = 51) and revealed a significantly lower mean value than in a healthy population. A novel mathematical model of the dynamic pattern of OS has been proposed. This model was implemented as a system of ordinary differential equations and assumes the induction of antioxidant protection enzymes being mediated by reactive oxygen species (ROS), with a subsequent decrease in the intracellular concentration of ROS. The rate of synthesis of antioxidant protection enzymes is limited by the ribosome synthesis rate, which depends on the number of active RG copies. Analysis of the model showed that the system always approaches a single point of stable equilibrium via the mechanism of damping oscillations, which to a certain extent resembles the dynamics of “predator-prey” interaction in the Lotka-Volterra model. The equilibrium ROS level inversely depends on the number of active RG copies. Our study allows us to explain the inconsistency of clinical data when detecting OS in IA and schizophrenia, suggesting a novel criterion for differential cytogenetic diagnostics of schizophrenia and IA, and to assume that antioxidant therapy should be effective only for children with a low number of active RG copies.
    09/2014; 4(5):363-373. DOI:10.1134/S2079086414050065
  • Source
    • "Small (64, 67), medium (72, 73), and large (108) sized DPBC trials and small and medium-sized open-label clinical trials (68, 70) demonstrate that novel treatments for children with ASD, which can address oxidative stress are associated with improvements in core ASD symptoms (68, 70, 72), sleep and gastrointestinal symptoms (64), hyperactivity, tantruming, and parental impression of general functioning (108), sensory-motor symptoms (67), and irritability (72, 73). These novel treatments include N-acetyl-l-cysteine (72, 73), methylcobalamin with (69, 70) and without (68) oral folinic acid, vitamin C (67), and a vitamin and mineral supplement that includes antioxidants, co-enzyme Q10, and B vitamins (64, 65). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies point to the effectiveness of novel treatments that address physiological abnormalities associated with autism spectrum disorder (ASD). This is significant because safe and effective treatments for ASD remain limited. These physiological abnormalities as well as studies addressing treatments of these abnormalities are reviewed in this article. Treatments commonly used to treat mitochondrial disease have been found to improve both core and associated ASD symptoms. Double-blind, placebo-controlled (DBPC) studies have investigated l-carnitine and a multivitamin containing B vitamins, antioxidants, vitamin E, and co-enzyme Q10 while non-blinded studies have investigated ubiquinol. Controlled and uncontrolled studies using folinic acid, a reduced form of folate, have reported marked improvements in core and associated ASD symptoms in some children with ASD and folate related pathway abnormities. Treatments that could address redox metabolism abnormalities include methylcobalamin with and without folinic acid in open-label studies and vitamin C and N-acetyl-l-cysteine in DBPC studies. These studies have reported improved core and associated ASD symptoms with these treatments. Lastly, both open-label and DBPC studies have reported improvements in core and associated ASD symptoms with tetrahydrobiopterin. Overall, these treatments were generally well-tolerated without significant adverse effects for most children, although we review the reported adverse effects in detail. This review provides evidence for potentially safe and effective treatments for core and associated symptoms of ASD that target underlying known physiological abnormalities associated with ASD. Further research is needed to define subgroups of children with ASD in which these treatments may be most effective as well as confirm their efficacy in DBPC, large-scale multicenter studies.
    Frontiers in Pediatrics 06/2014; 2:66. DOI:10.3389/fped.2014.00066
Show more